Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Gomella Discusses Informed Patient Decisions

April 16th 2012

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on Helping Patients Make Informed Medical Decisions

Dr. Crawford on Transperineal 3D Mapping Biopsy

April 13th 2012

Dr. David Crawford, from University of Colorado Health Sciences Center, Discusses Transperineal 3D Mapping Biopsy

Insights From Genomic Approaches to Oncology Discovery

April 12th 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Dr. Petrylak on Chemotherapy in Prostate Cancer

April 11th 2012

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Bone Microenvironment Promotes Bone Metastases in Prostate Cancer

April 10th 2012

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

Dr. Gomella Discusses the Challenges of PSA Screening

April 5th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the Challenges of PSA Screening

Dr. Sartor on Radium-223 in Early Prostate Cancer

April 4th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Radium-223 in Early Prostate Cancer

Dr. Dreicer Discusses Using Abiraterone Acetate

April 3rd 2012

Dr. Robert Dreicer, from the Taussig Cancer Institute at the Cleveland Clinic, Discusses Using Abiraterone Acetate

Current State of the Art for Treatment of Prostate Cancer

April 3rd 2012

An interview with Nicholas J. Vogelzang, MD, during the ASCO 2012 Genitourinary Cancers Symposium, about treatment of prostate cancer and unmet needs.

EBRT More Toxic, Costly Than Radical Prostatectomy or Brachytherapy

April 2nd 2012

EBRT led to more long-term toxicity and higher treatment-related costs compared with radical prostatectomy or brachyherapy.

Dr. Mohile On Prostate Cancer in Elderly Patients

March 30th 2012

Dr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients

Trial Affirms Survival Benefit of Novel Antiandrogen Signaling Agent MDV3100 in Advanced Prostate Cancer

March 30th 2012

The investigational agent MDV3100 extended survival in men with late-stage castration-resistant prostate cancer in the phase III AFFIRM trial.

Database Analysis Finds IMRT More Effective Than CRT and Proton Beam in Prostate Cancer

March 29th 2012

IMRT was superior to CRT in reducing recurrence and significant side effects in men with localized prostate cancer, according to a comparative effectiveness study based on the SEER-Medicare database.

PSA Testing Linked to Reduced Mortality

March 15th 2012

PSA testing was shown to significantly reduce mortality among men, but the test had no effect on all-cause mortality.

Consensus Elusive on Standard for Lowering Testosterone Levels

March 12th 2012

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

Zytiga Study Unblinded Following Positive Interim Analysis

March 9th 2012

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

No Increased Risk of Cardiovascular Death With Androgen Deprivation Therapy for Prostate Cancer

March 7th 2012

A meta-analysis shows no apparent association between androgen deprivation therapy and cardiovascular events and death in men with prostate cancer.

Dr. Gomella on the Cost of the Immunotherapy Sipuleucel-T

March 1st 2012

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Predicting Prostate Outcomes: Nomograms Help Patients Sort Options, But Caution Is Urged

February 29th 2012

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Yearly Prostate Cancer Screening Does Not Provide Mortality Benefit

February 28th 2012

Annual prostate cancer screening does not decrease mortality from prostate cancer more than opportunistic screening.